Saint-Luc university clinics- Catholic University of Louvain
The objective of the BELGICA trial is to evaluate if radiotherapy could be given in a more focused manner in patients with glioblastoma in order to reduce side effects and improve quality of life. The glioblastoma (GBM) is the most common and aggressive tumour originating from the brain, affecting approximately 600 patients per year in Belgium. The treatment consists in surgical resection of the tumour (when feasible), followed by a combination of radiotherapy and chemotherapy. Despite multimodal treatment (surgery, radiotherapy, and chemotherapy), the life expectancy of patients with GBM remains limited, with an average survival of 12-18 months and only 5% of patients surviving more than 5 years. In addition to limited survival, most patients with GBM experience impaired quality of life, both because of the disease and treatments. Radiotherapy is a treatment where radiation is used to kill cancer cells. In GBM, radiotherapy is targeted at the tumour (or tumour bed if the tumour was resected) with a safety margin around it (the "Clinical Target Volume" or CTV) to account for potential microscopic spread of the tumour. The downside of this safety margin is that a substantial amount of brain tissue is irradiated, which can lead to treatment toxicity. Reducing the CTV margin would enable to decrease the volume of brain being irradiated and could thereby allow to reduce the side effects of brain irradiation. The BELGICA trial (Achieving a BEtter outcome through Limiting the GlIoblastoma Clinical tArget volume) is a national multicentre trial which will evaluate if reducing the irradiation volume in glioblastoma is safe and allows for lowering side effects and improving quality of life.
Glioblastoma
Radiotherapy Side Effect
Radiotherapy (CTV=10mm)
Radiotherapy (CTV=15mm)
NA
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 347 participants |
| Masking : | SINGLE |
| Primary Purpose : | TREATMENT |
| Official Title : | Impact of Reducing the Irradiation Volume on Survival, Toxicity, and Quality of Life in Patients With Glioblastoma Treated With Radiochemotherapy: a Prospective Multicenter Randomised Study |
| Actual Study Start Date : | 2025-05-12 |
| Estimated Primary Completion Date : | 2031-10 |
| Estimated Study Completion Date : | 2031-10 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
OLV AZorg
Aalst, Belgium, 9300
Not yet recruiting
Epicura
Baudour, Belgium, 7331
Not yet recruiting
Saint Jan
Brugge, Belgium, 8000
Not yet recruiting
Saint-Luc university clinics
Brussels, Belgium, 1200
Not yet recruiting
Institute Jules Table
Bruxelles, Belgium, 1070
Not yet recruiting
Already brussel
Bruxelles, Belgium, 1090
Not yet recruiting
Hospital East Limburg (ZOL)
Genk, Belgium, 3600
Not yet recruiting
The Sint-Lucas
Gent, Belgium, 9000
Not yet recruiting
To Gent
Gent, Belgium, 9000
Not yet recruiting
Large Charleroi Hospital
Gilly, Belgium, 6060
Not yet recruiting
Jessa Hospital
Hasselt, Belgium, 3500
Not yet recruiting
AZ Groeninge
Kortrijk, Belgium, 8500
Not yet recruiting
chu helora
La Louvière, Belgium, 7100
Not yet recruiting
UZ Leuven
Leuven, Belgium, 3000
Not yet recruiting
CHU Liège
Liège, Belgium, 4000
Not yet recruiting
AZ Sint Maarten
Mechelen, Belgium, 2800
Not yet recruiting
André Vésale Hospital - Humani
Montigny-Le-Tilleul, Belgium, 6110
Not yet recruiting
CH Mouscron
Mouscron, Belgium, 7700
Not yet recruiting
Chu UCL Namur - Sainte Elizabeth
Namur, Belgium, 5000
Not yet recruiting
The delta
Roeselare, Belgium, 8800
Not yet recruiting
Europe clinics
Uccle, Belgium, 1180
Not yet recruiting
Chr Verviers
Verviers, Belgium, 4800
Not yet recruiting
Zas Augustine
Wilrijk, Belgium, 2610